{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:52:12Z","timestamp":1793040732377,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Enhancing levodopa efficacy through peripheral COMT inhibition and using continuous infusion are both established strategies for managing motor fluctuations. Both approaches aim to improve the pharmacokinetics of levodopa in order to maintain a steady delivery of levodopa to the brain, avoid the deep troughs in levodopa plasma concentrations associated with oral levodopa delivery, and thereby reduce OFF time. In this review, we describe the pharmacologic rationale for combining COMT inhibition with entacapone and continuous dopaminergic delivery that led to the development of levodopa\/entacapone\/carbidopa intestinal gel (LECIG). Entacapone is a peripheral COMT inhibitor, that effectively reduces the metabolism of levodopa to 3-O-methyldopa and increases the amount of levodopa that can be transported into the brain. However, entacapone has a short half-life and poor oral bioavailability that necessitates frequent dosing for optimal efficacy. Continuous infusion of entacapone allows for improved bioavailability from direct delivery to the duodenum\/jejunum. As such, lower overall levodopa doses can be given to achieve therapeutically effective concentrations. Accumulating real-world evidence with LECIG supports its use in managing motor fluctuations in patients whose control is becoming suboptimal with oral approaches. We provide an overview of the growing evidence base for its risk-benefit profile in patients with motor fluctuations.<\/jats:p>","DOI":"10.1007\/s00702-025-03006-x","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:02:15Z","timestamp":1756789335000},"page":"361-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["COMT inhibition with entacapone for patients with Parkinson\u2019s disease and motor complications: the novelty of continuous infusion"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0327-7584","authenticated-orcid":false,"given":"Peter","family":"Jenner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-7715","authenticated-orcid":false,"given":"Dag","family":"Nyholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"3006_CR1","doi-asserted-by":"publisher","first-page":"105357","DOI":"10.1016\/j.parkreldis.2023.105357","volume":"109","author":"JE Ahlskog","year":"2023","unstructured":"Ahlskog JE (2023) Levodopa, homocysteine and parkinson\u2019s disease: what\u2019s the problem? Parkinsonism Relat Disord 109:105357. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105357","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"3006_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/bdd.1986","volume":"36","author":"S Alqahtani","year":"2015","unstructured":"Alqahtani S, Kaddoumi A (2015) Development of a physiologically based pharmacokinetic\/pharmacodynamic model to identify mechanisms contributing to Entacapone low bioavailability. Biopharm Drug Dispos 36(9):587\u2013602. https:\/\/doi.org\/10.1002\/bdd.1986","journal-title":"Biopharm Drug Dispos"},{"key":"3006_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirto\u0161ek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, Amalia E, Arnold G, Bajenaru O, Bergmans B, Bjornara KA, Blackie J, Bode M, Bourgeois P, Bohlhalter S, Buraga I, Burkhard PR, Busson P, Calopa M, Clausen J, Danielsen EH, Defebvre L, Delvaux V, Dethy S, Dietrichs E, De Fabregues O, Gerhard R, Gusmaroli G, Hahn K, Hauptmann B, Henriksen T, Hernandez-Vara J, Jeanjean A, Kaiserova M, Kassubek J, Kimber T, Konitsiotis S, Kr\u00fcger R, Kulisevsky J, Leenders J, Lundqvist C, Ory Magne F, Marano P, Milanov I, Modugno N, Misbahuddin A, Nevrly M, Panayiotis Z, Pedersen KF, Pedersen SW, Perju-Dumbrava L, Ponsen MM, Popescu BO, Rijntjes M, Puente V, Redecker C, Schrader C, Sensi M, Simu M, Spanaki C, Storch A, Storstein A, Tomantschger V, van der Linden C, van Laar T, Viallet F, Witjas T, Wolz M, Zibetti M, Van Zandijcke M (2017) Levodopa-carbidopa intestinal gel in advanced parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3006_CR3","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","volume":"38","author":"A Antonini","year":"2021","unstructured":"Antonini A, Odin P, Pahwa R, Aldred J, Alobaidi A, Jalundhwala YJ, Kukreja P, Bergmann L, Inguva S, Bao Y, Chaudhuri KR (2021) The long-term impact of levodopa\/carbidopa intestinal gel on \u2018off\u2019-time in patients with advanced Parkinson\u2019s disease: a systematic review. Adv Ther 38(6):2854\u20132890. https:\/\/doi.org\/10.1007\/s12325-021-01747-1","journal-title":"Adv Ther"},{"issue":"2","key":"3006_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/03009734.2017.1285374","volume":"122","author":"SM Aquilonius","year":"2017","unstructured":"Aquilonius SM, Nyholm D (2017) Development of new Levodopa treatment strategies in parkinson\u2019s disease-from bedside to bench to bedside. Ups J Med Sci 122(2):71\u201377. https:\/\/doi.org\/10.1080\/03009734.2017.1285374","journal-title":"Ups J Med Sci"},{"key":"3006_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","volume":"132","author":"MF Bastide","year":"2015","unstructured":"Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdere P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bezard E (2015) Pathophysiology of L-dopa-induced motor and non-motor complications in parkinson\u2019s disease. Prog Neurobiol 132:96\u2013168. https:\/\/doi.org\/10.1016\/j.pneurobio.2015.07.002","journal-title":"Prog Neurobiol"},{"issue":"Suppl 1","key":"3006_CR7","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.parkreldis.2016.11.017","volume":"33","author":"R Bhidayasiri","year":"2016","unstructured":"Bhidayasiri R, Garcia Ruiz PJ, Henriksen T (2016) Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord 33(Suppl 1):S42\u2013S48. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.017","journal-title":"Parkinsonism Relat Disord"},{"key":"3006_CR8","doi-asserted-by":"crossref","unstructured":"Bialecka M, Kurzawski M, Roszmann A, Robowski P, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Jarosz M, Golab-Janowska M, Koziorowska-Gawron E, Drozdzik M, Slawek J (2012) Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in parkinson\u2019s disease. Pharmacogenet Genomics 22(10):716\u2013724","DOI":"10.1097\/FPC.0b013e32835693f7"},{"issue":"10","key":"3006_CR9","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1097\/mib.0000000000000143","volume":"20","author":"OK Bonderup","year":"2014","unstructured":"Bonderup OK, Fenger-Gr\u00f8n M, Wigh T, Pedersen L, Nielsen GL (2014) Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis 20(10):1702\u20131707. https:\/\/doi.org\/10.1097\/mib.0000000000000143","journal-title":"Inflamm Bowel Dis"},{"key":"3006_CR10","doi-asserted-by":"publisher","first-page":"173742","DOI":"10.1016\/j.ejphar.2020.173742","volume":"892","author":"MJ Bonifacio","year":"2021","unstructured":"Bonifacio MJ, Sousa F, Soares-da-Silva P (2021) Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by Levodopa in cynomolgus monkeys. Eur J Pharmacol 892:173742. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173742","journal-title":"Eur J Pharmacol"},{"issue":"3 Pt 1","key":"3006_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1212\/wnl.42.3.683","volume":"42","author":"T Brannan","year":"1992","unstructured":"Brannan T, Mart\u00ednez-Tica J, Yahr MD (1992) Catechol-O-methyltransferase Inhibition increases striatal L-dopa and dopamine: an in vivo study in rats. Neurology 42(3 Pt 1):683\u2013685. https:\/\/doi.org\/10.1212\/wnl.42.3.683","journal-title":"Neurology"},{"key":"3006_CR12","doi-asserted-by":"publisher","unstructured":"Broh\u00e9e S, Roze E, Grabli D, Letrillart H, Mantisi L, Foucard C, Hainque E, Cormier F, M\u00e9neret A, Hauw F (2025) Cognitive and psychiatric adverse effects of foslevodopa\/foscarbidopa in patients with Parkinson\u2019s disease. Movement Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70060","DOI":"10.1002\/mdc3.70060"},{"issue":"8","key":"3006_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00702-017-1698-7","volume":"124","author":"C Buhmann","year":"2017","unstructured":"Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H (2017) Levodopa\/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm 124(8):1005\u20131013. https:\/\/doi.org\/10.1007\/s00702-017-1698-7","journal-title":"J Neural Transm"},{"issue":"3","key":"3006_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/cpt1973143386","volume":"14","author":"DB Calne","year":"1973","unstructured":"Calne DB, Reid JL, Vakil SD (1973) Parkinsonism treated with 3-O-methyldopa. Clin Pharmacol Ther 14(3):386\u2013389. https:\/\/doi.org\/10.1002\/cpt1973143386","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3006_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/jpd-225105","volume":"13","author":"KR Chaudhuri","year":"2023","unstructured":"Chaudhuri KR, Kov\u00e1cs N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, Cubo E, Anca-Herschkovitsch M, Iansek R, Siddiqui MS, Simu M, Bergmann L, Ballina M, Kukreja P, Ladhani O, Jia J, Standaert DG (2023) Levodopa carbidopa intestinal gel in advanced parkinson\u2019s disease: DUOGLOBE final 3-Year results. J Parkinsons Dis 13(5):769\u2013783. https:\/\/doi.org\/10.3233\/jpd-225105","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"3006_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/WNF.0b013e31815c39aa","volume":"31","author":"M Contin","year":"2008","unstructured":"Contin M, Martinelli P, Scaglione C, Avoni P, Albani F, Riva R, Baruzzi A (2008) The effect of Entacapone on Levodopa rate of absorption and latency to motor response in patients with Parkinson disease. Clin Neuropharmacol 31(5):267\u2013271. https:\/\/doi.org\/10.1097\/WNF.0b013e31815c39aa","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"3006_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.22155","volume":"69","author":"JC Corvol","year":"2011","unstructured":"Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fi\u00e9vet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M (2011) The COMT Val158Met polymorphism affects the response to Entacapone in parkinson\u2019s disease: a randomized crossover clinical trial. Ann Neurol 69(1):111\u2013118. https:\/\/doi.org\/10.1002\/ana.22155","journal-title":"Ann Neurol"},{"issue":"9","key":"3006_CR18","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, \u015ami\u0142owska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European academy of neurology\/movement disorder Society - European section guideline on the treatment of parkinson\u2019s disease: I. Invasive therapies. Eur J Neurol 29(9):2580\u20132595. https:\/\/doi.org\/10.1111\/ene.15386","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"3006_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jns.2012.05.010","volume":"319","author":"H Doi","year":"2012","unstructured":"Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, Takahashi O (2012) Plasma Levodopa peak delay and impaired gastric emptying in parkinson\u2019s disease. J Neurol Sci 319(1\u20132):86\u201388. https:\/\/doi.org\/10.1016\/j.jns.2012.05.010","journal-title":"J Neurol Sci"},{"issue":"1","key":"3006_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR (2018) The Parkinson Pandemic\u2014a call to action. JAMA Neurol 75(1):9\u201310. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3299","journal-title":"JAMA Neurol"},{"issue":"5","key":"3006_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(24)00052-8","volume":"23","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O, Bou NSG (2024) Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for parkinson\u2019s disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 23(5):465\u2013476. https:\/\/doi.org\/10.1016\/S1474-4422(24)00052-8","journal-title":"Lancet Neurol"},{"issue":"9","key":"3006_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17460441.2020.1767580","volume":"15","author":"M Ettcheto","year":"2020","unstructured":"Ettcheto M, Oriol B, Elena S-L, Amanda C, MP R, Ester V, Jordi O, Carme A, Jaume F, Camins A (2020) The preclinical discovery and development of Opicapone for the treatment of Parkinson\u2019s disease. Expert Opin Drug Discov 15(9):993\u20131003. https:\/\/doi.org\/10.1080\/17460441.2020.1767580","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"3006_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord 30(4):500\u2013509. https:\/\/doi.org\/10.1002\/mds.26123","journal-title":"Mov Disord"},{"issue":"11","key":"3006_CR24","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1002\/mds.28703","volume":"36","author":"E Freire-Alvarez","year":"2021","unstructured":"Freire-Alvarez E, Kur\u010da E, Lopez Manzanares L, Pekkonen E, Spanaki C, Vanni P, Liu Y, S\u00e1nchez-Soli\u00f1o O, Barbato LM (2021) Levodopa-Carbidopa intestinal gel reduces dyskinesia in Parkinson\u2019s disease in a randomized trial. Mov Disord 36(11):2615\u20132623. https:\/\/doi.org\/10.1002\/mds.28703","journal-title":"Mov Disord"},{"key":"3006_CR25","doi-asserted-by":"publisher","unstructured":"Gandhi S, Zerenner T, Nodehi A, Lawton M, Marshall V, Al-Hajraf F, Grosset K, Morris H, Hu M, Ben-Shlomo Y, Grosset D (2024) Motor complications in Parkinson\u2019s disease: results from 3343 patients followed for up to 12 years. Movement Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.14044","DOI":"10.1002\/mdc3.14044"},{"key":"3006_CR26","doi-asserted-by":"publisher","unstructured":"Gretarsdottir HM, Widman E, Johansson A, Nyholm D (2021) Personalized Medicine approach in treating Parkinson\u2019s disease, using oral administration of Levodopa\/Carbidopa microtablets in clinical practice. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11080720","DOI":"10.3390\/jpm11080720"},{"issue":"2","key":"3006_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0031-6997(25)06681-5","volume":"27","author":"HC Guldberg","year":"1975","unstructured":"Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 27(2):135\u2013206","journal-title":"Pharmacol Rev"},{"issue":"7","key":"3006_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/ijnp\/pyac021","volume":"25","author":"S Habet","year":"2022","unstructured":"Habet S (2022) Clinical pharmacology of Entacapone (Comtan) from the FDA reviewer. Int J Neuropsychopharmacol 25(7):567\u2013575. https:\/\/doi.org\/10.1093\/ijnp\/pyac021","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Pt 2","key":"3006_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/brain\/107.2.487","volume":"107","author":"RJ Hardie","year":"1984","unstructured":"Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson\u2019s disease. A clinical and neuropharmacological study. Brain 107(Pt 2):487\u2013506","journal-title":"Brain"},{"issue":"1 Suppl 1","key":"3006_CR30","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1212\/wnl.62.1_suppl_1.s64","volume":"62","author":"RA Hauser","year":"2004","unstructured":"Hauser RA (2004) Levodopa\/carbidopa\/entacapone (Stalevo). Neurology 62(1 Suppl 1):S64\u201371. https:\/\/doi.org\/10.1212\/wnl.62.1_suppl_1.s64","journal-title":"Neurology"},{"issue":"Suppl 2","key":"3006_CR31","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","volume":"257","author":"O Hornykiewicz","year":"2010","unstructured":"Hornykiewicz O (2010) A brief history of Levodopa. J Neurol 257(Suppl 2):S249\u2013252. https:\/\/doi.org\/10.1007\/s00415-010-5741-y","journal-title":"J Neurol"},{"key":"3006_CR32","doi-asserted-by":"publisher","unstructured":"Jenner P (2024) Chapter One - Continuous dopaminergic stimulation and the transition to using continuous drug delivery in Parkinson\u2019s disease\u2014an introduction. In: Odin P, Chaudhuri KR, Falup-Pecurariu C (eds) International Review of Movement Disorders, vol 7. Academic Press, pp 1\u201315. https:\/\/doi.org\/10.1016\/bs.irmvd.2024.08.001","DOI":"10.1016\/bs.irmvd.2024.08.001"},{"issue":"5","key":"3006_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s002280050490","volume":"54","author":"KM Jorga","year":"1998","unstructured":"Jorga KM, Fotteler B, Heizmann P, Z\u00fcrcher G (1998) Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to parkinson\u2019s disease therapy. Eur J Clin Pharmacol 54(5):443\u2013447. https:\/\/doi.org\/10.1007\/s002280050490","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"3006_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mds.29410","volume":"38","author":"ST Jost","year":"2023","unstructured":"Jost ST, Kaldenbach M-A, Antonini A, Martinez-Martin P, Timmermann L, Odin P, Katzenschlager R, Borgohain R, Fasano A, Stocchi F, Hattori N, Kukkle PL, Rodr\u00edguez-Violante M, Falup-Pecurariu C, Schade S, Petry-Schmelzer JN, Metta V, Weintraub D, Deuschl G, Espay AJ, Tan E-K, Bhidayasiri R, Fung VSC, Cardoso F, Trenkwalder C, Jenner P, Ray Chaudhuri K, Dafsari HS, Parkinson, tI, Group MDSN-MPDS (2023) Levodopa dose equivalency in parkinson\u2019s disease: updated systematic review and proposals. Mov Disord 38(7):1236\u20131252. https:\/\/doi.org\/10.1002\/mds.29410","journal-title":"Mov Disord"},{"issue":"6","key":"3006_CR35","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","volume":"59","author":"S Kaakkola","year":"2000","unstructured":"Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in parkinson\u2019s disease. Drugs 59(6):1233\u20131250. https:\/\/doi.org\/10.2165\/00003495-200059060-00004","journal-title":"Drugs"},{"key":"3006_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/b978-0-12-381326-8.00009-0","volume":"95","author":"S Kaakkola","year":"2010","unstructured":"Kaakkola S (2010) Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson\u2019s disease. Int Rev Neurobiol 95:207\u2013225. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00009-0","journal-title":"Int Rev Neurobiol"},{"issue":"5","key":"3006_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0306-3623(94)90082-5","volume":"25","author":"S Kaakkola","year":"1994","unstructured":"Kaakkola S, Gordin A, M\u00e4nnist\u00f6 PT (1994) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 25(5):813\u2013824. https:\/\/doi.org\/10.1016\/0306-3623(94)90082-5","journal-title":"Gen Pharmacol"},{"issue":"1","key":"3006_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"HJ Kim","year":"2020","unstructured":"Kim HJ, Mason S, Foltynie T, Winder-Rhodes S, Barker RA, Williams-Gray CH (2020) Motor complications in Parkinson\u2019s disease: 13-year follow-up of the campaign cohort. Mov Disord 35(1):185\u2013190. https:\/\/doi.org\/10.1002\/mds.27882","journal-title":"Mov Disord"},{"issue":"5","key":"3006_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00228-009-0622-y","volume":"65","author":"M Kuoppam\u00e4ki","year":"2009","unstructured":"Kuoppam\u00e4ki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, H\u00e4nninen J, L\u00f6yttyniemi E, Kailaj\u00e4rvi M, Ruokoniemi P, Ellm\u00e9n J (2009) Comparison of Pharmacokinetic profile of Levodopa throughout the day between Levodopa\/carbidopa\/entacapone and Levodopa\/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65(5):443\u2013455. https:\/\/doi.org\/10.1007\/s00228-009-0622-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3006_CR40","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1212\/wnl.43.9.1698","volume":"43","author":"MC Kurth","year":"1993","unstructured":"Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JW (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa\/carbidopa in Parkinson\u2019s disease patients with \u2018on-off\u2019 fluctuations. Neurology 43(9):1698\u20131703. https:\/\/doi.org\/10.1212\/wnl.43.9.1698","journal-title":"Neurology"},{"issue":"4","key":"3006_CR42","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3233\/jpd-202022","volume":"10","author":"V Leta","year":"2020","unstructured":"Leta V, van Wamelen DJ, Sauerbier A, Jones S, Parry M, Rizos A, Chaudhuri KR (2020) Opicapone and Levodopa-Carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinson\u2019s Disease 10(4):1535\u20131539. https:\/\/doi.org\/10.3233\/jpd-202022","journal-title":"J Parkinson\u2019s Disease"},{"issue":"5","key":"3006_CR41","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/ene.15734","volume":"30","author":"V Leta","year":"2023","unstructured":"Leta V, Klingelhoefer L, Longardner K, Campagnolo M, Levent H, Aureli F, Metta V, Bhidayasiri R, Chung-Faye G, Falup-Pecurariu C, Stocchi F, Jenner P, Warnecke T, Ray Chaudhuri K (2023) Gastrointestinal barriers to Levodopa transport and absorption in Parkinson\u2019s disease. Eur J Neurol 30(5):1465\u20131480. https:\/\/doi.org\/10.1111\/ene.15734","journal-title":"Eur J Neurol"},{"key":"3006_CR43","doi-asserted-by":"publisher","unstructured":"Loureiro A, Rocha F, Santos A, Singh N, Bonif\u00e1cio M, Pinto R, Kiss L, Soares-da-Silva P (2022) Absorption, metabolism and excretion of Opicapone in human healthy volunteers. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15383","DOI":"10.1111\/bcp.15383"},{"issue":"4","key":"3006_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0031-6997(24)01423-6","volume":"51","author":"PT M\u00e4nnist\u00f6","year":"1999","unstructured":"M\u00e4nnist\u00f6 PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593\u2013628","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3006_CR45","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40120-024-00629-2","volume":"13","author":"PT M\u00e4nnist\u00f6","year":"2024","unstructured":"M\u00e4nnist\u00f6 PT, Ker\u00e4nen T, Reinikainen KJ, Hanttu A, Pollesello P (2024) The catechol O-Methyltransferase inhibitor Entacapone in the treatment of parkinson\u2019s disease: personal reflections on a First-in-Class drug development programme 40 years on. Neurol Ther 13(4):1039\u20131054. https:\/\/doi.org\/10.1007\/s40120-024-00629-2","journal-title":"Neurol Ther"},{"issue":"3","key":"3006_CR46","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ene.12846","volume":"23","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L (2016) Peripheral neuropathy associated with Levodopa-Carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 23(3):501\u2013509. https:\/\/doi.org\/10.1111\/ene.12846","journal-title":"Eur J Neurol"},{"key":"3006_CR47","doi-asserted-by":"publisher","first-page":"122901","DOI":"10.1016\/j.jns.2024.122901","volume":"457","author":"N Miyaue","year":"2024","unstructured":"Miyaue N, Ito Y, Yamanishi Y, Tada S, Ando R, Yabe H, Nagai M (2024) Optimization of oral Entacapone administration in patients undergoing Levodopa\u2013Carbidopa intestinal gel treatment. J Neurol Sci 457:122901. https:\/\/doi.org\/10.1016\/j.jns.2024.122901","journal-title":"J Neurol Sci"},{"issue":"3","key":"3006_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/WNF.0b013e31828f3385","volume":"36","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T (2013) Pharmacokinetic considerations for the use of Levodopa in the treatment of Parkinson disease: focus on Levodopa\/Carbidopa\/Entacapone for treatment of Levodopa-associated motor complications. Clin Neuropharmacol 36(3):84\u201391. https:\/\/doi.org\/10.1097\/WNF.0b013e31828f3385","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"3006_CR49","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","volume":"19","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Laar Tv, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013) Peripheral neuropathy in Parkinson\u2019s disease: Levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19(5):501\u2013507. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.02.006","journal-title":"Parkinsonism Relat Disord"},{"key":"3006_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/b978-0-12-381326-8.00003-x","volume":"95","author":"TT My\u00f6h\u00e4nen","year":"2010","unstructured":"My\u00f6h\u00e4nen TT, M\u00e4nnist\u00f6 PT (2010) Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? Int Rev Neurobiol 95:29\u201347. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00003-x","journal-title":"Int Rev Neurobiol"},{"key":"3006_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/b978-0-12-381326-8.00005-3","volume":"95","author":"E Nissinen","year":"2010","unstructured":"Nissinen E, M\u00e4nnist\u00f6 PT (2010) Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol 95:73\u2013118. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00005-3","journal-title":"Int Rev Neurobiol"},{"issue":"2","key":"3006_CR55","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.4.2.193","volume":"4","author":"D Nyholm","year":"2008","unstructured":"Nyholm D, Lennern\u00e4s H (2008) Irregular Gastrointestinal drug absorption in Parkinson\u2019s disease. Expert Opin Drug Metab Toxicol 4(2):193\u2013203. https:\/\/doi.org\/10.1517\/17425255.4.2.193","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3006_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/jpd-130244","volume":"4","author":"D Nyholm","year":"2014","unstructured":"Nyholm D, Stepien V (2014) Levodopa fractionation in Parkinson\u2019s disease. J Parkinsons Dis 4(1):89\u201396. https:\/\/doi.org\/10.3233\/jpd-130244","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"3006_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/00002826-200305000-00010","volume":"26","author":"D Nyholm","year":"2003","unstructured":"Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennern\u00e4s H, Nystr\u00f6m C, Aquilonius SM (2003) Optimizing Levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 26(3):156\u2013163. https:\/\/doi.org\/10.1097\/00002826-200305000-00010","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"3006_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/01.Wnl.0000149637.70961.4c","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H (2005) Duodenal Levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64(2):216\u2013223. https:\/\/doi.org\/10.1212\/01.Wnl.0000149637.70961.4c","journal-title":"Neurology"},{"issue":"6","key":"3006_CR54","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1468-1331.2011.03614.x","volume":"19","author":"D Nyholm","year":"2012","unstructured":"Nyholm D, Johansson A, Lennern\u00e4s H, Askmark H (2012) Levodopa infusion combined with Entacapone or Tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 19(6):820\u2013826. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03614.x","journal-title":"Eur J Neurol"},{"issue":"10","key":"3006_CR58","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.parkreldis.2015.07.020","volume":"21","author":"P Odin","year":"2015","unstructured":"Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson\u2019s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 21(10):1133\u20131144. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.020","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3006_CR59","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/mds.27690","volume":"34","author":"CW Olanow","year":"2019","unstructured":"Olanow CW (2019) Levodopa is the best symptomatic therapy for PD: nothing more, nothing less. Mov Disord 34(6):812\u2013815. https:\/\/doi.org\/10.1002\/mds.27690","journal-title":"Mov Disord"},{"issue":"8","key":"3006_CR62","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol 5(8):677\u2013687. https:\/\/doi.org\/10.1016\/S1474-4422(06)70521-X","journal-title":"Lancet Neurol"},{"issue":"2","key":"3006_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, Group LHS (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"issue":"10","key":"3006_CR60","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow CW, Calabresi P, Obeso JA (2020) Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities. Mov Disord 35(10):1731\u20131744. https:\/\/doi.org\/10.1002\/mds.28215","journal-title":"Mov Disord"},{"key":"3006_CR63","unstructured":"Ongentys 50\u00a0mg (2024) Hard capsules. Summary of product characteristics. BIAL Pahrmaceuticals"},{"issue":"12","key":"3006_CR65","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1002\/mdc3.14240","volume":"11","author":"M \u00d6thman","year":"2024","unstructured":"\u00d6thman M, Nyholm D (2024) A 4-year follow-up of Levodopa-Entacapone-Carbidopa intestinal gel treatment in Parkinson\u2019s disease. Mov Disord Clin Pract 11(12):1609\u20131612. https:\/\/doi.org\/10.1002\/mdc3.14240","journal-title":"Mov Disord Clin Pract"},{"key":"3006_CR66","doi-asserted-by":"publisher","unstructured":"\u00d6thman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the Levodopa-Entacapone-Carbidopa intestinal gel in clinical practice. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11040254","DOI":"10.3390\/jpm11040254"},{"issue":"1","key":"3006_CR64","doi-asserted-by":"publisher","first-page":"e16582","DOI":"10.1111\/ene.16582","volume":"32","author":"M \u00d6thman","year":"2025","unstructured":"\u00d6thman M, Bergquist F, Odin P, Scharfenort M, Johansson A, Markaki I, Svenningsson P, Dizdar N, Nyholm D (2025) Levodopa-entacapone-carbidopa intestinal gel: data from the Swedish National registry for Parkinson\u2019s disease. Eur J Neurol 32(1):e16582. https:\/\/doi.org\/10.1111\/ene.16582","journal-title":"Eur J Neurol"},{"issue":"11","key":"3006_CR67","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00702-023-02708-4","volume":"130","author":"Z Pirto\u0161ek","year":"2023","unstructured":"Pirto\u0161ek Z, Leta V, Jenner P, V\u00e9rin M (2023) Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson\u2019s disease? J Neural Transm (Vienna) 130(11):1395\u20131404. https:\/\/doi.org\/10.1007\/s00702-023-02708-4","journal-title":"J Neural Transm (Vienna)"},{"key":"3006_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3389\/fneur.2020.00419","volume":"11","author":"W Poewe","year":"2020","unstructured":"Poewe W, Bergmann L, Robieson WZ, Antonini A (2020) Predictors of response for off time improvement with Levodopa-Carbidopa intestinal gel treatment: an analysis of the GLORIA registry. Front Neurol 11:419. https:\/\/doi.org\/10.3389\/fneur.2020.00419","journal-title":"Front Neurol"},{"issue":"8295","key":"3006_CR69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/s0140-6736(82)90442-1","volume":"2","author":"N Quinn","year":"1982","unstructured":"Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson\u2019s disease: response to intravenous infusion of Levodopa. Lancet 2(8295):412\u2013415. https:\/\/doi.org\/10.1016\/s0140-6736(82)90442-1","journal-title":"Lancet"},{"issue":"3","key":"3006_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/s0304-3940(97)00502-8","volume":"230","author":"I Reenil\u00e4","year":"1997","unstructured":"Reenil\u00e4 I, Tuomainen P, Soinila S, M\u00e4nnist\u00f6 PT (1997) Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci Lett 230(3):155\u2013158. https:\/\/doi.org\/10.1016\/s0304-3940(97)00502-8","journal-title":"Neurosci Lett"},{"issue":"40","key":"3006_CR71","doi-asserted-by":"publisher","first-page":"E1377","DOI":"10.1503\/cmaj.220680","volume":"194","author":"DM Rodrigues","year":"2022","unstructured":"Rodrigues DM, Hsieh E, Bernstein M, Juurlink DN (2022) Lymphocytic colitis associated with Entacapone. CMAJ 194(40):E1377\u2013e1380. https:\/\/doi.org\/10.1503\/cmaj.220680","journal-title":"CMAJ"},{"issue":"2","key":"3006_CR72","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/mdc3.12688","volume":"6","author":"A Romagnolo","year":"2019","unstructured":"Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L (2019) Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 6(2):96\u2013103. https:\/\/doi.org\/10.1002\/mdc3.12688","journal-title":"Mov Disord Clin Pract"},{"key":"3006_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BFb0036121","volume":"120","author":"JA Roth","year":"1992","unstructured":"Roth JA (1992) Membrane-bound catechol-O-methyltransferase: a Reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol 120:1\u201329. https:\/\/doi.org\/10.1007\/BFb0036121","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"6","key":"3006_CR74","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s002280050657","volume":"55","author":"J Rouru","year":"1999","unstructured":"Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral Entacapone after frequent multiple dosing and effects on Levodopa disposition. Eur J Clin Pharmacol 55(6):461\u2013467. https:\/\/doi.org\/10.1007\/s002280050657","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3006_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ana.410240116","volume":"24","author":"JI Sage","year":"1988","unstructured":"Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC (1988) Long-term duodenal infusion of Levodopa for motor fluctuations in parkinsonism. Ann Neurol 24(1):87\u201389. https:\/\/doi.org\/10.1002\/ana.410240116","journal-title":"Ann Neurol"},{"issue":"1","key":"3006_CR76","doi-asserted-by":"publisher","first-page":"e16535","DOI":"10.1111\/ene.16535","volume":"32","author":"D Santos-Garc\u00eda","year":"2025","unstructured":"Santos-Garc\u00eda D, L\u00f3pez-Manzanares L, Muro I, Lorenzo-Barreto P, Casas Pe\u00f1a E, Garc\u00eda-Ramos R, Fern\u00e1ndez Valle T, Morata-Mart\u00ednez C, Baviera-Mu\u00f1oz R, Mart\u00ednez-Torres I, \u00c1lvarez-Sauco M, Alonso-Modino D, Legarda I, Valero-Garc\u00eda MF, Su\u00e1rez-Mu\u00f1oz JA, Mart\u00ednez-Castrillo JC, Perona AB, Salom JM, Cubo E, Valero-Merino C, L\u00f3pez-Ariztegui N, S\u00e1nchez Alonso P, Novo Ponte S, Gamo Gonz\u00e1lez E, Mart\u00edn Garc\u00eda R, Espinosa R, Carmona M, Feliz CE, Garc\u00eda Ru\u00edz P, Mu\u00f1oz Ru\u00edz T, Fern\u00e1ndez Rodr\u00edguez B, Mata M (2025) Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: a real-world data study. Eur J Neurol 32(1):e16535. https:\/\/doi.org\/10.1111\/ene.16535","journal-title":"Eur J Neurol"},{"issue":"2","key":"3006_CR77","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: a randomized crossover study. Mov Disord 32(2):283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disord"},{"key":"3006_CR78","doi-asserted-by":"crossref","unstructured":"Senek M, Nyholm D, Nielsen EI (2020) Population pharmacokinetics of Levodopa gel infusion in Parkinson\u2019s disease: effects of Entacapone infusion and genetic polymorphism. Sci Rep 10:18057","DOI":"10.1038\/s41598-020-75052-2"},{"issue":"1","key":"3006_CR79","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjno-2023-000573","volume":"6","author":"V Sisodia","year":"2024","unstructured":"Sisodia V, Dubbeld L, De Bie RMA, Duarte GS, Costa J, Dijk JM (2024) Efficacy and safety of adjunctive oral therapy in Parkinson\u2019s disease with motor complications: a systematic review and network meta-analysis. BMJ Neurol Open 6(1):e000573. https:\/\/doi.org\/10.1136\/bmjno-2023-000573","journal-title":"BMJ Neurol Open"},{"issue":"6","key":"3006_CR80","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/mds.870120616","volume":"12","author":"LA Smith","year":"1997","unstructured":"Smith LA, Gordin A, Jenner P, Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12(6):935\u2013945. https:\/\/doi.org\/10.1002\/mds.870120616","journal-title":"Mov Disord"},{"issue":"12","key":"3006_CR81","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/s1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O\u2019Neill D, Robieson WZ, Spindler MA, Standaert DG, Talapala S, Vaou EO, Zheng H, Facheris MF, Hauser RA (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109. https:\/\/doi.org\/10.1016\/s1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"3006_CR82","doi-asserted-by":"publisher","first-page":"300648","DOI":"10.1016\/j.hpr.2022.300648","volume":"28","author":"MJ Steel","year":"2022","unstructured":"Steel MJ, Conner J, Nelles S, Kirsch R (2022) A case of Carbidopa\/Levodopa associated colitis mimicking inflammatory bowel disease. Hum Pathol Rep 28:300648. https:\/\/doi.org\/10.1016\/j.hpr.2022.300648","journal-title":"Hum Pathol Rep"},{"issue":"3","key":"3006_CR84","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10072-003-0138-7","volume":"24","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Vacca L, Grassini P, Battaglia G, Onofrj M, Valente M, Ruggieri S (2003) Optimizing Levodopa pharmacokinetics in Parkinson\u2019s disease: the role of COMT inhibitor. Neurol Sci 24(3):217\u2013218. https:\/\/doi.org\/10.1007\/s10072-003-0138-7","journal-title":"Neurol Sci"},{"issue":"1","key":"3006_CR83","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating Levodopa\/Carbidopa therapy with and without Entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18\u201327. https:\/\/doi.org\/10.1002\/ana.22060","journal-title":"Ann Neurol"},{"key":"3006_CR85","unstructured":"Swedish Medical Products Agency (2018) Public Assessment Report for Lecigon (entacapone, carbidopa (monohydrate), levodopa) SE\/H\/1986\/01\/E\/01. Available at https:\/\/docetp.mpa.se\/LMF\/Lecigon%20intestinal%20gel%20ENG%20PAR_09001bee813fbfeb.pdf"},{"issue":"3","key":"3006_CR86","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1097\/mjt.0000000000001707","volume":"31","author":"JA Sz\u00e1sz","year":"2024","unstructured":"Sz\u00e1sz JA, Dulamea AO, Constantin VA, Mure\u015fanu DF, Dumbrav\u0103 LP, Tiu C, Jianu DC, Simu M, Ene A, Axelerad A, Falup-Pecurariu C, Lungu M, Danci AG, Sabau M, Strilciuc \u015e, Popescu BO (2024) Levodopa-Carbidopa-Entacapone intestinal gel in advanced Parkinson disease: a multicenter real-life experience. Am J Ther 31(3):e209\u2013e218. https:\/\/doi.org\/10.1097\/mjt.0000000000001707","journal-title":"Am J Ther"},{"key":"3006_CR87","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/pharmaceutics16040453","volume":"16","author":"S Szatm\u00e1ri","year":"2024","unstructured":"Szatm\u00e1ri S, Szasz J, Orban-Kis K, Bar\u00f3ti B, Bataga S, Ciorba M, Nagy E, Neagoe R, Mih\u00e1ly I, Sz\u00e1sz P, Kelemen K, Frigy A, Szilveszter M, Constantin V (2024) Levodopa\u2013Entacapone\u2013Carbidopa intestinal gel in the treatment of advanced Parkinson\u2019s disease: a single center real-world experience. Pharmaceutics 16:453. https:\/\/doi.org\/10.3390\/pharmaceutics16040453","journal-title":"Pharmaceutics"},{"issue":"3","key":"3006_CR88","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/mdc3.12303","volume":"3","author":"J Timpka","year":"2016","unstructured":"Timpka J, Henriksen T, Odin P (2016) Non-oral continuous drug delivery techniques in Parkinson\u2019s disease: for whom, when, and how? Mov Disord Clin Pract 3(3):221\u2013229. https:\/\/doi.org\/10.1002\/mdc3.12303","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"3006_CR89","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR (2017) Advanced Parkinson\u2019s or complex phase Parkinson\u2019s disease? Re-evaluation is needed. J Neural Transm (Vienna) 124(12):1529\u20131537. https:\/\/doi.org\/10.1007\/s00702-017-1799-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"3006_CR90","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0304-3940(91)90422-p","volume":"132","author":"H Tohgi","year":"1991","unstructured":"Tohgi H, Abe T, Kikuchi T, Takahashi S, Nozaki Y (1991) The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson\u2019s disease. Neurosci Lett 132(1):19\u201322. https:\/\/doi.org\/10.1016\/0304-3940(91)90422-p","journal-title":"Neurosci Lett"},{"issue":"1","key":"3006_CR91","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41531-021-00246-y","volume":"7","author":"F Valldeoriola","year":"2021","unstructured":"Valldeoriola F, Catal\u00e1n MJ, Escamilla-Sevilla F, Freire E, Olivares J, Cubo E, Garc\u00eda DS, Calopa M, Mart\u00ednez-Mart\u00edn P, Parra JC, Arroyo G, Arbelo JM (2021) Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease. Npj Parkinson\u2019s Disease 7(1):108. https:\/\/doi.org\/10.1038\/s41531-021-00246-y","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"2","key":"3006_CR92","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/mdc3.13926","volume":"11","author":"V Viljaharju","year":"2024","unstructured":"Viljaharju V, Mertsalmi T, Pauls KAM, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E (2024) Levodopa-Entacapone-Carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease: a Single-Center study of 30 patients. Mov Disord Clin Pract 11(2):159\u2013165. https:\/\/doi.org\/10.1002\/mdc3.13926","journal-title":"Mov Disord Clin Pract"},{"issue":"9","key":"3006_CR93","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1002\/mds.27447","volume":"33","author":"M Wanneveich","year":"2018","unstructured":"Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P (2018) Projections of prevalence, lifetime risk, and life expectancy of Parkinson\u2019s disease (2010\u20132030) in France. Mov Disord 33(9):1449\u20131455. https:\/\/doi.org\/10.1002\/mds.27447","journal-title":"Mov Disord"},{"key":"3006_CR94","doi-asserted-by":"publisher","unstructured":"Weiss D, Jost WH, Sz\u00e1sz JA, Pirto\u0161ek Z, Milanov I, Tomantschger V, Kov\u00e1cs N, Staines H, Amlani B, Smith N, van Laar T Levodopa\u2013Entacapone\u2013Carbidopa Intrajejunal Infusion in Advanced Parkinson\u2019s Disease \u2013 Interim Analysis of the ELEGANCE Study. Movement Disorders Clinical Practice n\/a (n\/a). https:\/\/doi.org\/10.1002\/mdc3.70046","DOI":"10.1002\/mdc3.70046"},{"issue":"10","key":"3006_CR95","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.parkreldis.2014.07.011","volume":"20","author":"H Wu","year":"2014","unstructured":"Wu H, Dong F, Wang Y, Xiao Q, Yang Q, Zhao J, Quinn TJ, Chen SD, Liu J (2014) Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson\u2019s disease. Parkinsonism Relat Disord 20(10):1094\u20131096. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.07.011","journal-title":"Parkinsonism Relat Disord"},{"key":"3006_CR96","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jns.2017.05.023","volume":"378","author":"P Zis","year":"2017","unstructured":"Zis P, Gr\u00fcnewald RA, Chaudhuri RK, Hadjivassiliou M (2017) Peripheral neuropathy in idiopathic Parkinson\u2019s disease: a systematic review. J Neurol Sci 378:204\u2013209. https:\/\/doi.org\/10.1016\/j.jns.2017.05.023","journal-title":"J Neurol Sci"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03006-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:19:47Z","timestamp":1769692787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3006"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03006-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Peter Jenner reports honoraria for consultancy and advisory boards from Britannia Pharmaceuticals, AbbVie, Bial, Cerevel, Kyowa Kirin, Supernus, and Zambon. Dag Nyholm reports honoraria for consultancy and lectures from Britannia Pharmaceuticals, Stada, NordicInfu Care, Integrative Research Laboratories Sweden AB, Navamedic, Orion, and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}